2024
Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma
Husain Z, Rybkin A, Lee V, Young M, Eskander A, Burtness B, Park H. Evaluation of a Novel Prognostic System for Overall Survival in Surgically Resected Oral Cavity Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e759-e760. DOI: 10.1016/j.ijrobp.2024.07.1668.Peer-Reviewed Original ResearchLymphovascular space invasionOral cavity carcinomaOverall survivalIntermediate-riskHigh riskT3/4 diseaseDistant metastasisN stageStandard riskPrediction of distant metastasisGrade 3 tumorsMedian follow-upNational Cancer DatabasePathological risk factorsOral cavity cancerKaplan-Meier methodLog-rank testSubsets of patientsHospital-based cohortClinical trial stratificationHigh-volume hospitalsT3/4 tumorsMedian followSurgical resectionIndividualized treatment selectionLong-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Burtness B, Flamand Y, Quon H, Weinstein G, Mehra R, Garcia J, Kim S, O'malley B, Ozer E, Koch W, Gross N, Bell R, Patel M, Lango M, Morris L, Smith R, Karakla D, Richmon J, Holsinger F, Ferris R. Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2024, 42: 6009-6009. DOI: 10.1200/jco.2024.42.16_suppl.6009.Peer-Reviewed Original ResearchProgression-free survivalIntermediate risk patientsExtranodal extensionOverall survivalPhase II trialRisk patientsSmoking historyPack-yearsPrimary siteLong-term follow-upFavorable pathologic characteristicsMature outcome dataPrescribed radiation doseECOG-ACRIN Cancer Research GroupPost-operative radiationIncreased recurrence riskKaplan-Meier methodLog-rank testPost-operative managementCancer Research GroupHPV+ OPCWeekly cisplatinMedian followN1 diseaseN1 patients
2022
Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Mehra R, Flamand Y, Quon H, Garcia J, Weinstein G, Duvvuri U, O'Malley B, Ozer E, Thomas G, Koch W, Gross N, Bell R, Saba N, Lango M, Bayon R, Burtness B, Ferris R. Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2022, 40: 6077-6077. DOI: 10.1200/jco.2022.40.16_suppl.6077.Peer-Reviewed Original ResearchProgression-free survivalOropharynx cancerOverall survivalSmoking statusTransoral surgeryAdjuvant treatmentPerformance statusPrimary siteECOG-ACRIN Cancer Research GroupFirst treatment approachHistory of smokingPhase II trialKaplan-Meier methodLog-rank testCancer Research GroupSignificant differencesWilcoxon rank sum testChi-square testRank sum testDefinitive chemoradiationEvaluable ptsOS ratesEfficacy outcomesExtranodal extensionII trial
2020
Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.
Rischin D, Harrington K, Greil R, Soulieres D, Tahara M, Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Lin J, Gumuscu B, Swaby R, Burtness B. Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state. Journal Of Clinical Oncology 2020, 38: 6530-6530. DOI: 10.1200/jco.2020.38.15_suppl.6530.Peer-Reviewed Original ResearchTreatment-related adverse eventsIncurable recurrentMetastatic subgroupM HNSCCSuperior OSMedian OSPFS benefitGrade 3MS subgroupsRecurrent/metastatic headNeck squamous cell carcinomaKEYNOTE-048 trialPD-L1 CPSDisease statesECOG performance statusFirst-line therapyPD-L1 statusKaplan-Meier methodTotal study populationSquamous cell carcinomaCox regression modelKEYNOTE-048Metastatic headAdverse eventsHazard ratioKEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Harrington K, Rischin D, Greil R, Soulieres D, Tahara M, Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Zhang Y, Gumuscu B, Swaby R, Burtness B. KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2020, 38: 6505-6505. DOI: 10.1200/jco.2020.38.15_suppl.6505.Peer-Reviewed Original ResearchPD-L1 CPSSubsequent anticancer therapyM HNSCCMedian PFS2Subsequent therapyRecurrent/metastatic headNeck squamous cell carcinomaNext-line therapyObjective tumor progressionImmune checkpoint inhibitorsFirst-line therapyKaplan-Meier methodAnticancer therapySquamous cell carcinomaCox regression modelTotal populationKEYNOTE-048Superior OSCheckpoint inhibitorsMetastatic headSystemic therapyComparable safetyCell carcinomaFavorable safetyPatient outcomes
2017
Ent Instructions for Authors
Wang LS, Handorf EA, Ridge JA, Burtness BA, Lango MN, Mehra R, Liu JC, Galloway TJ. Ent Instructions for Authors. Ear, Nose & Throat Journal 2017, 96: 271-272. PMID: 28719713, PMCID: PMC7549076, DOI: 10.1177/014556131709600703.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChemoradiotherapy, AdjuvantChi-Square DistributionCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLogistic ModelsLymph NodesMaleMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalPrognosisRadiotherapy, AdjuvantRetrospective StudiesSkin NeoplasmsConceptsNonmelanoma skin cancerProgression-free survivalConcurrent chemoradiationLymph nodesLocoregional controlOverall survivalSkin cancerLocalized skin cancerLymph node measurementLymph node positiveGrade 4 thrombocytopeniaPositive lymph nodesSingle tertiary centerKaplan-Meier methodAggressive clinical courseAdjuvant concurrent chemoradiationAdvanced nonmelanoma skin cancersChi-square testAdjuvant radiationAdjuvant therapyClinical courseLocal recurrenceNode positiveTertiary centerCRT patientsA Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma
Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough W, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA. A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma. JAMA Oncology 2017, 3: 358-365. PMID: 27737449, DOI: 10.1001/jamaoncol.2016.4581.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell cancerAJCC/UICC systemStaging systemStage IAStage IBHuman papillomavirusPrognostic abilityUICC systemAJCC/UICC staging systemStage IICurrent American Joint CommitteeOropharyngeal squamous cell carcinomaInternational Cancer Control (UICC) staging systemOropharyngeal cancer NetworkNational Cancer DatabasePrimary radiation therapyOverall survival rateAmerican Joint CommitteeCancer/UnionEdition staging systemKaplan-Meier methodSquamous cell cancerNovel staging systemSquamous cell carcinomaLog-rank test
2014
Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303
Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA. Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303. Clinical Cancer Research 2014, 20: 3023-3032. PMID: 24700741, PMCID: PMC4049169, DOI: 10.1158/1078-0432.ccr-14-0113.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarboplatinCarcinoma, Squamous CellCetuximabChemoradiotherapyDisease-Free SurvivalDrug Resistance, NeoplasmFemaleFluorescent Antibody TechniqueHead and Neck NeoplasmsHumansInduction ChemotherapyKaplan-Meier EstimateMaleMiddle AgedMitogen-Activated Protein Kinase KinasesPaclitaxelPhosphatidylinositol 3-KinasesPrognosisProportional Hazards ModelsProto-Oncogene Proteins c-aktRas ProteinsSignal TransductionSquamous Cell Carcinoma of Head and NeckTissue Array AnalysisConceptsProgression-free survivalEvent-free survivalPhase II trialOverall survivalII trialTissue microarrayStage III/IV headMultivariable Cox proportional hazards modelsMultivariable Cox regression analysisNeck squamous cell cancerRAS/MAPK/ERKCox proportional hazards modelInsulin-like growth factor 1 receptorLarge prospective studiesCox regression analysisInferior overall survivalKaplan-Meier methodSquamous cell cancerLog-rank testGrowth factor 1 receptorProportional hazards modelPI3K/Akt pathwayFactor 1 receptorPI3K/AktEGF receptorFreedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer.
Thomay A, Su S, Friedant A, Ruth K, Astsaturov I, Burtness B, Denlinger C, Dotan E, Hall M, Meyer J, Shah P, Cohen S, Scott W. Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer. Journal Of Clinical Oncology 2014, 32: 126-126. DOI: 10.1200/jco.2014.32.3_suppl.126.Peer-Reviewed Original ResearchEsophageal cancerOverall survivalGroup BLandmark analysisGroup ANeoadjuvant treatment regimenKaplan-Meier methodEsophageal cancer patientsProspective databaseR0 resectionDistant recurrencePatient demographicsSurgery patientsMeier methodMore recurrencesOperative complicationsPathologic responseTreatment regimenCancer patientsOperative procedurePatientsLarge seriesRecurrenceSurvival curvesPropensity score
2013
Dysplasia at the margin? Investigating the case for subsequent therapy in ‘Low-Risk’ squamous cell carcinoma of the oral tongue
Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ. Dysplasia at the margin? Investigating the case for subsequent therapy in ‘Low-Risk’ squamous cell carcinoma of the oral tongue. Oral Oncology 2013, 49: 1083-1087. PMID: 24054332, PMCID: PMC4037753, DOI: 10.1016/j.oraloncology.2013.08.001.Peer-Reviewed Original ResearchConceptsDisease-free survivalFox Chase Cancer CenterModerate dysplasiaOverall survivalLocal controlOral tongueSevere dysplasiaMild dysplasiaActuarial local controlInferior local controlKaplan-Meier methodOral tongue cancerWorse local controlSquamous cell carcinomaEarly-stage cancerAdditional therapyMeier methodResection marginsSubsequent therapyEntire cohortTongue cancerCancer CenterCell carcinomaPathology reportsFinal margins
2012
Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC).
Psyrri A, Lee J, Pectasides E, Vassilakopoulou M, Burtness B, Rimm D, Wanebo H, Forastiere A. Predictors for response to cetuximab in a prospective clinical trial (E2303) of patients with head and neck squamous cell carcinoma (HNSCC). Journal Of Clinical Oncology 2012, 30: 5576-5576. DOI: 10.1200/jco.2012.30.15_suppl.5576.Peer-Reviewed Original ResearchClinical trialsEastern Cooperative Oncology Group Phase II TrialExact testStage III/IV HNSCCMultivariate Cox proportional hazards modelMultivariate Cox regression analysisERK1/2 levelsNeck squamous cell carcinomaCox proportional hazards modelEpidermal growth factor receptor inhibitorsPhase II clinical trialGrowth factor receptor inhibitorsManagement of HNSCCPhase II trialCox regression analysisKaplan-Meier methodProspective clinical trialsSquamous cell carcinomaLog-rank testAssociation of biomarkersProportional hazards modelFisher's exact testLogistic regression modelsProtein expression levelsWeekly cetuximab